Cited by 24Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

1-year weight change after diabetes diagnosis and long-term incidence and sustainability of remission of type 2 diabetes in real-world settings in Hong Kong: An observational cohort study

Open access
Wu, Hongjiang, Yang, Aimin, Lau, Eric S. H., Zhang, Xinge, Fan, Baoqi, Ma, Ronald C. W., Kong, Alice P. S., Chow, Elaine +3 more·2024·PLOS Medicine

Abstract

Background: Clinical trials have demonstrated that remission of type 2 diabetes can be achieved following sustained weight loss. However, the feasibility of achieving diabetes remission through weight management in real-world settings remains unclear. In this study, we aimed to examine the association of weight change at 1 year after diabetes diagnosis with long-term incidence and sustainability of type 2 diabetes remission in real-world settings in Hong Kong. Methods and findings: This was a population-based observational cohort study. The territory-wide Risk Assessment and Management Programme for Diabetes Mellitus (RAMP-DM) provides regular comprehensive assessments of metabolic control and complication screening for people with diabetes in Hong Kong. We included 37,326 people with newly diagnosed type 2 diabetes who were enrolled in the RAMP-DM between 2000 and 2017, followed until 2019. Diabetes remission was defined as 2 consecutive HbA1c <6.5% measurements at least 6 months apart in the absence of glucose-lowering drugs (GLDs) and with no record of GLDs at least 3 months before these measurements. During a median follow-up of 7.9 years, 6.1% (2,279) of people achieved diabetes remission, with an incidence rate of 7.8 (95% CI: 7.5, 8.1) per 1,000 person-years. After adjusting for age at diabetes diagnosis, sex, assessment year, body mass index, other metabolic indices, smoking, alcohol drinking, and medication use, the hazard ratio (HR) for diabetes remission was 3.28 (95% CI: 2.75, 3.92; p < 0.001) for people with ≥10% weight loss within 1 year of diagnosis, 2.29 (95% CI: 2.03, 2.59; p < 0.001) for those with 5% to 9.9% weight loss, and 1.34 (95% CI: 1.22, 1.47; p < 0.001) for those with 0% to 4.9% weight loss compared to people with weight gain. During a median follow-up of 3.1 years, 67.2% (1,531) of people who had achieved diabetes remission returned to hyperglycaemia, with an incidence rate of 184.8 (95% CI: 175.5, 194.0) per 1,000 person-years. The adjusted HR for returning to hyperglycaemia was 0.52 (95% CI: 0.41, 0.65; p < 0.001) for people with ≥10% weight loss, 0.78 (95% CI: 0.68, 0.92; p = 0.002) for those with 5% to 9.9% weight loss, and 0.90 (95% CI: 0.80, 1.01; p = 0.073) for those with 0% to 4.9% weight loss compared to people with weight gain. Diabetes remission was associated with a 31% (HR: 0.69, 95% CI: 0.52, 0.93; p = 0.014) decreased risk of all-cause mortality. The main limitation of the study is that the reliability of HbA1c used to define diabetes remission can be affected by other medical conditions. Furthermore, we did not have data on bariatric surgery. Conclusions: In this study, greater weight loss within the first year of diabetes diagnosis was associated with an increased likelihood of achieving diabetes remission and a decreased risk of returning to hyperglycaemia among those who had achieved diabetes remission. However, both the incidence of diabetes remission and the probability of its long-term sustainability were low with conventional management in real-world settings, in an era when the importance of weight loss was not fully appreciated. Our study provides evidence for policymakers to design and implement early weight management interventions and diabetes remission initiatives.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1004327

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • For people who already have diabetes, lifestyle modification and pharmacological treatment, as well as blood pressure and cholesterol control, can delay progression to complications and reduce mortality, or even help with remission, especially if started early.

    “For people who already have diabetes, lifestyle modification and pharmacological treatment, as well as blood pressure and cholesterol control, can delay progression to complications and reduce mortality, or even help with remission, especially if started early.1,2,58–62”

    From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [60]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 26

  1. [2]McTigue KM, Wellman R, Nauman E, Anau J, Coley RY, Odor A, et al. Comparing the 5-year diabetes outcomes of sleeve gastrectomy and gastric bypass: The National Patient-Centered Clinical Research Network (PCORNet) bariatric study. JAMA Surg. 2020; 155(5): e200087. doi: 10.1001/jamasurg.2020.0087 32129809 PMC7057171 · DOI
  2. [4]Taheri S, Zaghloul H, Chagoury O, Elhadad S, Ahmed SH, El Khatib N, et al. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2020; 8(6): 477– 489. doi: 10.1016/S2213-8587(20)30117-0 32445735 · DOI · Paper page
  3. [5]Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, Clark JM, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016; 4(11): 913– 921. doi: 10.1016/S2213-8587(16)30162-0 27595918 PMC5094846 · DOI · Paper page
  4. [6]Hansen AH, Wangberg SC, Årsand E. Lifestyle changes among people with type 2 diabetes are associated with participation in online groups and time since diagnosis. BMC Health Serv Res. 2021; 21(1): 688. doi: 10.1186/s12913-021-06660-5 34253211 PMC8276517 · DOI
  5. [7]Schneider KL, Andrews C, Hovey KM, Seguin RA, Manini T, Lamonte MJ, et al. Change in physical activity after a diabetes diagnosis: opportunity for intervention. Med Sci Sports Exerc. 2014; 46(1): 84– 91. doi: 10.1249/MSS.0b013e3182a33010 23860414 PMC4028702 · DOI
  6. [8]Chan JCN, Lim L-L, Luk AOY, Ozaki R, Kong APS, Ma RCW, et al. From Hong Kong Diabetes Register to JADE Program to RAMP-DM for data-driven actions. Diabetes Care. 2019; 42(11): 2022– 2031. doi: 10.2337/dci19-0003 31530658 · DOI
  7. [9]Wu H, Lau ESH, Yang A, Zhang X, Ma RCW, Kong APS, et al. Data Resource Profile: The Hong Kong Diabetes Surveillance Database (HKDSD). Int J Epidemiol. 2022; 51(2): e9– e17. doi: 10.1093/ije/dyab252 34904159 · DOI
  8. [10]Wu H, Lau ESH, Ma RCW, Kong APS, Wild SH, Goggins W, et al. Secular trends in all-cause and cause-specific mortality rates in people with diabetes in Hong Kong, 2001–2016: a retrospective cohort study. Diabetologia. 2020; 63(4): 757– 66. doi: 10.1007/s00125-019-05074-7 31942668 · DOI
  9. [11]Wu H, Lau ESH, Yang A, Zhang X, Fan B, Ma RCW, et al. Age-specific population attributable risk factors for all-cause and cause-specific mortality in type 2 diabetes: An analysis of a 6-year prospective cohort study of over 360,000 people in Hong Kong. PLoS Med. 2023; 20(1): e1004173. doi: 10.1371/journal.pmed.1004173 36716342 PMC9925230 · DOI
  10. [12]Wu H, Yang A, Lau ESH, Zhang X, Fan B, Shi M, et al. Age- and sex-specific hospital bed-day rates in people with and without type 2 diabetes: A territory-wide population-based cohort study of 1.5 million people in Hong Kong. PLoS Med. 2023; 20(8): e1004261. doi: 10.1371/journal.pmed.1004261 37540646 PMC10403124 · DOI
  11. [13]Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, et al. Consensus report: Definition and interpretation of remission in type 2 diabetes. Diabetes Care. 2021; 44(10): 2438– 2444. doi: 10.2337/dci21-0034 34462270 PMC8929179 · DOI · Paper page
  12. [14]Holman N, Wild SH, Khunti K, Knighton P, O’Keefe J, Bakhai C, et al. Incidence and characteristics of remission of Ttype 2 diabetes in England: A cohort study using the National Diabetes Audit. Diabetes Care. 2022; 45(5): 1151– 1161. 10.2337/dc21-2136 35320360 PMC9174970 · DOI
  13. [15]Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010; 340: b5087. doi: 10.1136/bmj.b5087 20228141 · DOI
  14. [16]Captieux M, Fleetwood K, Kennon B, Sattar N, Lindsay R, Guthrie B, et al. Epidemiology of type 2 diabetes remission in Scotland in 2019: A cross-sectional population-based study. PLoS Med. 2021; 18(11): e1003828. doi: 10.1371/journal.pmed.1003828 34727107 PMC8562803 · DOI
  15. [17]Stensrud MJ, Hernán MA. Why test for proportional hazards? JAMA. 2020; 323(14): 1401– 1402. doi: 10.1001/jama.2020.1267 32167523 PMC11983487 · DOI
  16. [18]White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011; 30(4): 377– 399. doi: 10.1002/sim.4067 21225900 · DOI · Paper page
  17. [21]Fan B, Wu H, Shi M, Yang A, Lau ESH, Tam CHT, et al. Associations of the HOMA2-%B and HOMA2-IR with progression to diabetes and glycaemic deterioration in young and middle-aged Chinese. Diabetes Metab Res Rev. 2022; 38(5): e3525. doi: 10.1002/dmrr.3525 35174618 PMC9542522 · DOI
  18. [23]Taylor R, Barnes AC, Hollingsworth KG, Irvine KM, Solovyova AS, Clark L, et al. Aetiology of type 2 diabetes in people with a ’normal’ body mass index: testing the personal fat threshold hypothesis. Clin Sci (Lond). 2023; 137(16): 1333– 46. doi: 10.1042/CS20230586 37593846 PMC10472166 · DOI · Paper page
  19. [25]Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia. 2008; 51(10): 1781– 1789. doi: 10.1007/s00125-008-1116-7 18726585 · DOI · Paper page
  20. [26]Gregg EW, Chen H, Wagenknecht LE, Clark JM, Delahanty LM, Bantle J, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012; 308(23): 2489– 2496. doi: 10.1001/jama.2012.67929 23288372 PMC4771522 · DOI · Paper page
  21. [27]Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023. doi: 10.1016/S0140-6736(23)01200-X 37385275 · DOI · Paper page
  22. [28]Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021; 397(10278): 971– 984. 10.1016/s0140-6736(21)00213-0 33667417 · DOI · Paper page
  23. [30]Ke C, Stukel TA, Shah BR, Lau E, Ma RC, So W-Y, et al. Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: A population-based observational study. PLoS Med. 2020; 17(9): e1003316–e. 10.1371/journal.pmed.1003316 32946450 PMC7500681 · DOI
  24. [31]Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med. 2014; 29(2): 388– 394. doi: 10.1007/s11606-013-2595-x 24002631 PMC3912281 · DOI · Paper page
  25. [33]Steven S, Hollingsworth KG, Small PK, Woodcock SA, Pucci A, Aribasala B, et al. Calorie restriction and not glucagon-like peptide-1 explains the acute improvement in glucose control after gastric bypass in Type 2 diabetes. Diabet Med. 2016; 33(12): 1723– 1731. doi: 10.1111/dme.13257 27589584 · DOI · Paper page
  26. [35]Wu E, Luk A, Wong SK, So WY, Kong A, Chow F, et al. Health-related quality of life after bariatric surgery and its correlation with glycaemic status in Hong Kong Chinese adults. Obes Surg. 2016; 26(3): 538– 545. > doi: 10.1007/s11695-015-1787-3 26160705 · DOI

Cited by

Sorted by citations

Authors
Wu, H., Yang, A., Lau, E. S. H., Zhang, X., Fan, B., Ma, R. C. W., Kong, A. P. S., Chow, E., So, W.-Y., Chan, J. C. N., & Luk, A. O. Y.
Affiliations
  • Chinese University of Hong Kong (HK)
  • Hospital Authority (HK)
Corresponding author
Luk, Andrea O. Y.
Venue
PLOS Medicine
Published
2024-01-23
Volume
21
Issue
1
Pages
e1004327
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W4391135321
Cited by
24
References
9
Citations by year
2026: 11 · 2025: 3 · 2024: 10
FWCI
7.85
Type
journal article
Language
en
Open access
Locations
  • PLoS Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Amgen
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Biogen
  • Hospital Authority
  • Novo Nordisk
  • Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, diabetes remission, weight loss, weight management, newly diagnosed diabetes, HbA1c, real-world environments, Hong Kong, metabolic control, diabetes complications screening, body mass index, smoking, alcohol consumption, medication use
MeSH terms
Diabetes Mellitus, Type 2, Glucose, Glycated Hemoglobin, Hong Kong, Humans, Hyperglycemia, Reproducibility of Results, Cohort Studies, Weight Gain, Weight Loss, Incidence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review